• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    11/12/24 2:45:16 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email
    SC 13G 1 tm2427940d2_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

     

    (Amendment No. )*

     

    ArriVent Biopharma, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value per Share

    (Title of Class of Securities)

     

    04272N102

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨        Rule 13d-1(b)

     

    ¨        Rule 13d-1(c)

     

    x       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Page 1 of 11 Pages

    Exhibit Index Contained on Page 10

     

     

     

     

     

    CUSIP NO. 04272N102 13 G Page  2 of 11

     

    1

    NAME OF REPORTING PERSONS      

     

    Sofinnova Venture Partners XI, L.P. (“SVP XI”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a)     ¨     (b)    x     

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    1,696,752 shares, except that Sofinnova Management XI, L.P. (“SM XI LP”), the general partner of SVP XI, may be deemed to have sole voting power, Sofinnova Management XI, L.L.C. (“SM XI LLC”), the general partner of SM XI LP, may be deemed to have sole voting power, and Dr. James I. Healy (“Healy”) and Dr. Maha Katabi (“Katabi”), the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    1,696,752 shares, except that SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,696,752
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1%
    12 TYPE OF REPORTING PERSON (See Instructions) PN

     

     

     

     

    CUSIP NO. 04272N102 13 G Page  3 of 11

     

    1

    NAME OF REPORTING PERSONS      

    Sofinnova Management XI, L.P. (“SM XI LP”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a)     ¨     (b)    x    

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,696,752
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1%
    12 TYPE OF REPORTING PERSON (See Instructions) PN

     

     

     

     

    CUSIP NO. 04272N102 13 G Page  4 of 11

     

    1

    NAME OF REPORTING PERSONS      

    Sofinnova Management XI, L.L.C. (“SM XI LLC”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a)     ¨     (b)    x    

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,696,752
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1%
    12 TYPE OF REPORTING PERSON (See Instructions) OO

     

     

     

     

    CUSIP NO. 04272N102 13 G Page 5 of 11

     

    1

    NAME OF REPORTING PERSONS   
       
    Dr. James I. Healy (“Healy”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     ¨     (b)    x    

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0 shares.

    6

    SHARED VOTING POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power over the shares owned by SVP XI, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared power to vote these shares.

    7

    SOLE DISPOSITIVE POWER

     

    0 shares.

    8

    SHARED DISPOSITIVE POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared power to dispose of these shares.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,696,752
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.1%
    12 TYPE OF REPORTING PERSON IN

     

     

     

     

    CUSIP NO. 04272N102 13 G Page 6 of 11

     

    1

    NAME OF REPORTING PERSONS     
     
    Dr. Maha Katabi (“Katabi”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     ¨     (b)    x    

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canadian Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0 shares.

    6

    SHARED VOTING POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power over the shares owned by SVP XI, and Katabi, a managing member of SM XI LLC, may be deemed to have shared power to vote these shares.

    7

    SOLE DISPOSITIVE POWER

     

    0 shares.

    8

    SHARED DISPOSITIVE POWER

     

    1,696,752 shares, all of which are owned directly by SVP XI. SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Katabi, a managing member of SM XI LLC, may be deemed to have shared dispositive power over these shares.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,696,752
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.1%
    12 TYPE OF REPORTING PERSON IN

     

     

     

     

    CUSIP NO. 04272N102 13 G Page 7 of 11

     

    Introductory Note: This joint statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, $0.0001 Par Value per Share (“Common Stock”), of ArriVent Biopharma, Inc. (the “Issuer”).

     

    ITEM 1(A).NAME OF ISSUER

     

    ArriVent Biopharma, Inc.

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

    18 Campus Boulevard Suite 100

    Newtown Square, PA 19073

     

    ITEM 2(A).NAME OF PERSONS FILING

     

    This Statement is filed by Sofinnova Venture Partners XI, L.P. (“SVP XI”), Sofinnova Management XI, L.P. (“SM XI LP”), Sofinnova Management XI, L.L.C. (“SM XI LLC”), Dr. James I. Healy (“Healy”) and Dr. Maha Katabi (“Katabi”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    ITEM 2(B).ADDRESS OF PRINCIPAL BUSINESS OFFICE

     

    The address for each of the Reporting Persons is:

     

    c/o Sofinnova Investments, Inc.

    3000 Sand Hill Road, Bldg. 3, Suite 150

    Menlo Park, CA 94025

     

    ITEM 2(C).

    CITIZENSHIP

     

    Each of SVP XI and SM XI LP is a Delaware limited partnership. SM XI LLC is a Delaware limited liability company. Healy is a U.S. citizen. Katabi is a Canadian citizen.

     

    ITEM 2(D).

    TITLE OF CLASS OF SECURITIES

     

    Common Stock, $0.0001 Par Value per Share

     

    ITEM 2(E).CUSIP NUMBER

    04272N102

     

    ITEM 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

     

     

     

    CUSIP NO. 04272N102 13 G Page 8 of 11

     

    ITEM 4.OWNERSHIP

     

    (a)Amount beneficially owned:

     

    See Row 9 of cover page for each Reporting Person.*

     

    (b)Percent of Class:

     

    See Row 11 of cover page for each Reporting Person.*

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Row 5 of cover page for each Reporting Person.*

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.*

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Row 8 of cover page for each Reporting Person.

     

    *Except to the extent of a Reporting Person’s pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Under certain circumstances set forth in the limited partnership agreement of each of SVP XI and SM XI LP and the limited liability company agreement of SM XI LLC, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF THE GROUP

    Not applicable.

     

    ITEM 10.CERTIFICATIONS

    Not applicable.

     

     

     

     

    CUSIP NO. 04272N102 13 G Page 9 of 11

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:         November 12, 2024

     

      SOFINNOVA VENTURE PARTNERS XI, L.P., a Delaware Limited Partnership
       
      By: SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership
      Its: General Partner
       
      By: SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
      Its: General Partner
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership
       
      By: SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
      Its: General Partner
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      DR. JAMES I. HEALY
      DR. MAHA KATABI
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact

     

    *Executed pursuant to a Power of Attorney already on file with the appropriate agencies.

     

     

     

     

    CUSIP NO. 74257L108 13 G Page 10 of 11

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 11

     

     

     

     

    CUSIP NO. 74257L108 13 G Page 11 of 11

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of ArriVent Biopharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     

    Date:     November 12, 2024

     

      SOFINNOVA VENTURE PARTNERS XI, L.P., a Delaware Limited Partnership
       
      By: SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership
      Its: General Partner
       
      By: SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
      Its: General Partner
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership
       
      By: SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
      Its: General Partner
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact
       
      DR. JAMES I. HEALY
      DR. MAHA KATABI
       
      By: /s/ Nathalie Auber
        Nathalie Auber
        Attorney-in-Fact

     

    *Executed pursuant to a Power of Attorney already on file with the appropriate agencies.

     

     

     

    Get the next $AVBP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    7/10/2025$33.00Buy
    Goldman
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    2/20/2024$35.00Buy
    Jefferies
    2/20/2024$27.00Buy
    Goldman
    2/20/2024$30.00Buy
    Citigroup
    More analyst ratings

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

    16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line patientsConfirmed CNS (central nervous system) responses with firmonertinib including complete responses (CRs) by BICRFirmonertinib rapidly decreased or cleared PACC circulating tumor DNA (ctDNA) in frontline patients across PACC mutation types (frequent, less frequent and compound PACC) consistent with broad PACC activityEnrollment of the first patient in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant non-small cell

    9/9/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports Second Quarter 2025 Financial Results

    Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC projected to be in early 2026Cash and investments of $254.5 million as of June 30, 2025, in addition to $81.1 million raised in the public offering in July 2025, expected to fund our operating plan to mid-2027 NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Arri

    8/11/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on ArriVent BioPharma with a new price target

    Goldman resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $33.00

    7/10/25 8:52:29 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on ArriVent BioPharma with a new price target

    B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00

    3/20/25 7:59:08 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on ArriVent BioPharma with a new price target

    Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

    3/10/25 7:18:09 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Leadership Updates

    Live Leadership Updates

    View All

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports First Quarter 2025 Financial Results

    Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

    5/12/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

    NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

    4/28/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    12/4/24 4:32:39 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/14/24 4:33:47 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/12/24 2:45:16 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Lachapelle Robin exercised 11,153 shares at a strike of $2.28, increasing direct ownership by 9% to 135,736 units (SEC Form 4)

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    7/15/25 7:00:15 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parsey Merdad

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:33:08 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Peterson Kristine

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:32:41 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ArriVent BioPharma Inc.

    SCHEDULE 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    10/15/25 4:07:02 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

    9/9/25 8:00:13 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.

    SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

    8/14/25 4:59:38 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care